Corcept Therapeutics Incorporated (0I3Q)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 87.75 |
|---|---|
| 52-week range | 28.67 – 126.57 |
| Return, 1 month / 3 months | −24.0% / −2.8% |
| Return, 1 year / 3 years | – / – |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 29 |
| Volatility (1 year) | 102.3% |
| Worst drawdown (1 year) | -63.7% |
| Average daily value traded | 0.10M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Corcept Therapeutics Incorporated is a pharmaceutical company that develops and markets medicines that modulate the hormone cortisol. Its main commercial product is used to treat patients with Cushing's syndrome, a condition caused by excess cortisol, and the company also studies additional cortisol-modulating compounds for other serious endocrine and stress-related conditions. Corcept works with physicians and patients in the United States and is headquartered in Menlo Park, California.
Corcept Therapeutics Incorporated trades under the code 0I3Q on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Corcept Therapeutics Incorporated (0I3Q) trades on the London Stock Exchange in UK. It last closed at USD 87.75 on 27 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 2,228 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 17.8% | ||
| From 52-week high | -28.7% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -2.8% | ||
| 6-month return | 91.5% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 8 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 102.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -63.7% | ||
| Liquidity | 30 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −24.2% |
|---|---|
| 1 month | −24.0% |
| 3 months | −2.8% |
| 6 months | +91.5% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 114.21 / 74.51 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.89 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.